---
title: "Teva Pharmaceutical Industries Limited (TEVA.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/TEVA.US/overview.md"
symbol: "TEVA.US"
name: "Teva Pharmaceutical Industries Limited"
parent: "https://longbridge.com/zh-HK/quote/TEVA.US.md"
datetime: "2026-04-06T11:19:39.197Z"
locales:
  - [en](https://longbridge.com/en/quote/TEVA.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TEVA.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TEVA.US/overview.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/TEVA.US/overview.md) | [简体中文](https://longbridge.com/zh-CN/quote/TEVA.US/overview.md)


# Teva Pharmaceutical Industries Limited (TEVA.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | Pharmaceuticals |
| 交易所 | US Market |
| 地址 | 124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel |
| 官網 | [www.tevapharm.com](https://www.tevapharm.com) |

## 公司簡介

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Richard D. Francis | President, CEO & Director |
| Sol J. Barer | Independent Chairman of the Board |
| Eliyahu Sharon Kalif | Executive VP & CFO |
| Eric A. Hughes | Executive VP of Global R&D and Chief Medical Officer |
| Christine Fox | Executive VP of US Commercial & Head of Innovative Franchise |
| Evan Lippman | Executive Vice President of Business Development |
| Rosemary A. Crane | Independent Director |
| Gerald M. Lieberman | Independent Director |
| Roberto Agostino Mignone | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| Norges Bank Investment Management | 6.40% | 2025-12-31 |
| Migdal Mutual Funds Ltd. | 5.69% | 2026-01-20 |
| Phoenix Investments & Finances Ltd | 5.19% | 2025-12-31 |
| BlackRock, Inc. | 5.01% | 2026-02-27 |
| Harel Insurance Investments & Financial Services Ltd | 3.87% | 2025-12-31 |
| The Vanguard Group, Inc. | 3.84% | 2026-02-28 |
| Menora Mivtachim Pensions & Gemel Ltd. | 3.38% | 2025-12-31 |
| Clal Financial Management Ltd | 3.21% | 2025-12-31 |
| Lingotto Investment Management LLP | 2.44% | 2025-12-31 |
| FMR LLC | 2.23% | 2025-12-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| UNITED STATES | 9186000000 | 53.23% |
| Europe | 5040000000 | 29.2% |
| International Markets | 2162000000 | 12.53% |
| Other Activities | 870000000 | 5.04% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Teva Pharmaceutical Industries Limited Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "UNITED STATES",
        "ratio": 53.23
      },
      {
        "segment": "Europe",
        "ratio": 29.2
      },
      {
        "segment": "International Markets",
        "ratio": 12.53
      },
      {
        "segment": "Other Activities",
        "ratio": 5.04
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**